Janowsky E C, Kupper L L, Hulka B S
Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, 27599, USA.
N Engl J Med. 2000 Mar 16;342(11):781-90. doi: 10.1056/NEJM200003163421105.
The postulated relation between silicone breast implants and the risk of connective-tissue and autoimmune diseases has generated intense medical and legal interest during the past decade. The salience of the issue persists, despite the fact that a great deal of research has been conducted on this subject. To provide a stronger quantitative basis for addressing the postulated relation, we applied several techniques of meta-analysis that combine, compare, and summarize the results of existing relevant studies.
We searched data bases and reviewed citations in relevant articles to identify studies that met prestated inclusion criteria. Nine cohort studies, nine case-control studies, and two cross-sectional studies were included in our meta-analyses. We conducted meta-analyses of the results of these studies, both with and without adjustment for confounding factors, and a separate analysis restricted to studies of silicone-gel-filled breast implants. Finally, we estimated the annual number of new cases of connective-tissue disease that could be attributed to breast implants.
There was no evidence that breast implants were associated with a significant increase in the summary adjusted relative risk of individual connective-tissue diseases (rheumatoid arthritis, 1.04 [95 percent confidence interval, 0.72 to 1.51]; systemic lupus erythematosus, 0.65 [95 percent confidence interval, 0.35 to 1.23]; scleroderma or systemic sclerosis, 1.01 [95 percent confidence interval, 0.59 to 1.73]; and Sjögren's syndrome, 1.42 [95 percent confidence interval, 0.65 to 3.11]); all definite connective-tissue diseases combined (0.80; 95 percent confidence interval, 0.62 to 1.04); or other autoimmune or rheumatic conditions (0.96; 95 percent confidence interval, 0.74 to 1.25). Nor was there evidence of significantly increased risk in the unadjusted analyses or in the analysis restricted to silicone-gel-filled implants.
On the basis of our meta-analyses, there was no evidence of an association between breast implants in general, or silicone-gel-filled breast implants specifically, and any of the individual connective-tissue diseases, all definite connective-tissue diseases combined, or other autoimmune or rheumatic conditions. From a public health perspective, breast implants appear to have a minimal effect on the number of women in whom connective-tissue diseases develop, and the elimination of implants would not be likely to reduce the incidence of connective-tissue diseases.
在过去十年中,关于硅胶乳房植入物与结缔组织疾病和自身免疫性疾病风险之间的假定关系引发了医学界和法律界的浓厚兴趣。尽管已经针对该主题开展了大量研究,但该问题的重要性依然存在。为了为探讨这种假定关系提供更有力的定量依据,我们应用了几种荟萃分析技术,这些技术可以合并、比较和总结现有相关研究的结果。
我们检索了数据库,并查阅了相关文章中的参考文献,以确定符合预先设定纳入标准的研究。我们的荟萃分析纳入了9项队列研究、9项病例对照研究和2项横断面研究。我们对这些研究的结果进行了荟萃分析,包括对混杂因素进行调整和未调整的情况,并单独对仅针对硅胶填充乳房植入物的研究进行了分析。最后,我们估计了可归因于乳房植入物的结缔组织疾病新发病例的年度数量。
没有证据表明乳房植入物与个体结缔组织疾病(类风湿关节炎,1.04[95%置信区间,0.72至1.51];系统性红斑狼疮,0.65[95%置信区间,0.35至1.23];硬皮病或系统性硬化症,1.01[95%置信区间,0.59至1.73];干燥综合征,1.42[95%置信区间,0.65至3.11])、所有明确的结缔组织疾病合并(0.80;95%置信区间,0.62至1.04)或其他自身免疫性或风湿性疾病(0.96;95%置信区间,0.74至1.25)的汇总调整后相对风险显著增加有关。在未调整分析或仅针对硅胶填充植入物的分析中,也没有证据表明风险显著增加。
基于我们的荟萃分析,没有证据表明一般的乳房植入物,特别是硅胶填充乳房植入物,与任何个体结缔组织疾病、所有明确的结缔组织疾病合并或其他自身免疫性或风湿性疾病之间存在关联。从公共卫生角度来看,乳房植入物似乎对发生结缔组织疾病的女性数量影响极小,并且去除植入物不太可能降低结缔组织疾病的发病率。